The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
According to instruction manuals released by Primerdesign, the devices can be operated via a Mac or PC. There is no complex programming or data analysis required. DNA samples obtained via nasal swabs are placed into reaction tubes that are then processed by the machines on-site.
Easier to use. Samples are added into reaction tubes, then machine will process and read the results. NO extraction
Methods needed. This would be a big hit worldwide.
I agreed with your valuation but there is no takeover by AZ. Novacyt is not a speculative buy but is still very undervalued with strong fundamentals. Again there is no takeover or buy out by AZ. Imo
Imo, Novacyt is still very undervalued and if I'm not mistaken it is the only Aim company with a projected profit of more than £100 million year end.
No dilutions -No issue of Equities . Majority of Aim companies love issues of equities.
My projected Revenue year end more than £200 millon
Net profit of more than £100 million .
Management team is one of the best in AIM companies.
I believe The company always delivers. The Pathflow lateral test Covid 19 test would be launched before year end. The good thing about this pathflow test is It is not laboratory based test. It xan ve ysed in care homes , airports , gp surgeries etc. £10 is my target .